Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2014

01-10-2014 | Original Article

The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma

Authors: Ana S. Soares, Vera M. Costa, Carmen Diniz, Paula Fresco

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2014

Login to get access

Abstract

Purpose

Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the deadliest form of skin cancer. Melanoma progression is associated with the abrogation of normal controls that limit cell proliferation, migration, and invasion, eventually leading to metastasis. Based on the variety of cellular mechanisms involved in metastatic progression, we aimed to evaluate the effect of inosine (50 μM) and of the combination of Cl-IB-MECA (10 μM) with paclitaxel (10 ng/mL) on several stages of melanoma progression.

Methods

Proliferation, migration, adhesion, invasion, and colony formation assays were performed on human C32 and A375 metastatic melanoma cells. Levels of ERK1/2 were also determined using an ELISA kit. Moreover, mouse aortic rings were treated with vascular endothelial growth factor in order to assess the microvessel sprouting (an indicator of angiogenesis) in the presence of the referred compounds.

Results

We demonstrate that inosine induced, through A3 adenosine receptor activation, proliferation, migration, adhesion, and invasion on C32 and A375 melanoma cells, although with dissimilar importance on the two melanoma cell lines. Inosine also increased colony formation on A375 cells. Levels of ERK1/2 were increased after inosine exposure and that increase was dependent on A3 adenosine receptor activation in both cell lines. Moreover, microvessel sprouting stimulated by inosine was decreased by the combination of Cl-IB-MECA with paclitaxel.

Conclusions

Cl-IB-MECA combined with paclitaxel was able to impair almost all of the referred metastatic related mechanisms induced by inosine, making this approach a valuable tool for combinatory therapy against metastatic melanoma.
Literature
1.
2.
3.
4.
Soares AS, Costa VM, Diniz C, Fresco P (2013) Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: a new possible therapeutic strategy for melanoma. Biomed Pharmacother 67(8):777–789PubMedCrossRef
5.
Soares AS, Costa VM, Diniz C, Fresco P (2014) Combination of Cl-IB-MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR-dependent autophagy and mitotic catastrophe on human melanoma cells. J Cancer Res Clin Oncol. doi:10.​1007/​s00432-014-1645-z PubMed
6.
7.
Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10(2):153–163PubMedCrossRef
8.
Haass NK, Smalley KS, Li L, Herlyn M (2005) Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res Spons Eur Soc Pigment Cell Res Int Pigment Cell Soc 18(3):150–159CrossRef
9.
Attoub S, Arafat K, Gelaude A, Al Sultan MA, Bracke M, Collin P, Takahashi T, Adrian TE, De Wever O (2013) Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. PLoS One 8(1):e53087PubMedCrossRefPubMedCentral
10.
Huang YW, Baluna R, Vitetta ES (1997) Adhesion molecules as targets for cancer therapy. Histol Histopathol 12(2):467–477PubMed
11.
Yamazoe Y, Tsubaki M, Matsuoka H, Satou T, Itoh T, Kusunoki T, Kidera Y, Tanimori Y, Shoji K, Nakamura H, Ogaki M, Nishiura S, Nishida S (2009) Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int 33(10):1087–1094PubMedCrossRef
12.
Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28(31):2796–2805PubMedCrossRefPubMedCentral
13.
Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Update Rev Comment Antimicrob Anticancer Chemother 13(1–2):16–28CrossRef
14.
15.
Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71(8):2892–2900PubMedCrossRef
16.
17.
Soares AS, Costa VM, Diniz C, Fresco P (2014) Inosine strongly enhances human C32 melanoma cells proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K pathways. Basic Clin Pharmacol Toxicol. doi:10.​1111/​bcpt.​12280
18.
Vannoni D, Bernini A, Carlucci F, Civitelli S, Di Pietro MC, Leoncini R, Rosi F, Tabucchi A, Tanzini G, Marinello E (2004) Enzyme activities controlling adenosine levels in normal and neoplastic tissues. Med Oncol 21(2):187–195PubMedCrossRef
19.
Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41:775–787PubMedCrossRef
20.
Pirincci N, Gecit I, Gunes M, Yuksel MB, Kaba M, Tanik S, Demir H, Aslan M (2012) Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer. Clinics 67(12):1443–1446PubMedCrossRefPubMedCentral
21.
Aghaei M, Karami-Tehrani F, Salami S, Atri M (2005) Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin Biochem 38(10):887–891PubMedCrossRef
22.
Zanini D, Schmatz R, Pelinson LP, Pimentel VC, da Costa P, Cardoso AM, Martins CC, Schetinger CC, Baldissareli J, do Carmo Araujo M, Oliveira L, Chiesa J, Morsch VM, Leal DB, Schetinger MR (2013) Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer. Mol Cell Biochem 374(1–2):137–148PubMedCrossRef
23.
Shafy A, Molinie V, Cortes-Morichetti M, Hupertan V, Lila N, Chachques JC (2012) Comparison of the effects of adenosine, inosine, and their combination as an adjunct to reperfusion in the treatment of acute myocardial infarction. ISRN Cardiol 2012:326809PubMedCrossRefPubMedCentral
24.
25.
Gessi S, Varani K, Merighi S, Cattabriga E, Avitabile A, Gavioli R, Fortini C, Leung E, Mac Lennan S, Borea PA (2004) Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 65(3):711–719PubMedCrossRef
26.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–63PubMedCrossRef
27.
Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329–333PubMedCrossRef
28.
Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra SK (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 5(4):309–320PubMedCrossRef
29.
Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6 K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28(29):2621–2633PubMedCrossRefPubMedCentral
30.
Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D’Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K (2012) Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 7(1):89–104CrossRef
31.
Jin X, Shepherd RK, Duling BR, Linden J (1997) Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Investig 100(11):2849–2857PubMedCrossRefPubMedCentral
32.
Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 107(4):1547–1552PubMedCrossRefPubMedCentral
33.
Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, Borea PA (2002) Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119(4):923–933PubMedCrossRef
34.
Wolber C, Fozard JR (2005) The receptor mechanism mediating the contractile response to adenosine on lung parenchymal strips from actively sensitised, allergen-challenged Brown Norway rats. Naunyn-Schmiedeberg’s Arch Pharmacol 371(2):158–168CrossRef
35.
Mlejnek P, Dolezel P, Frydrych I (2013) Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. J Physiol Biochem 69(3):405–417PubMedCrossRef
36.
37.
Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC Jr (2011) Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res 71(17):5806–5817PubMedCrossRefPubMedCentral
38.
Tran TA, Gillet L, Roger S, Besson P, White E, Le Guennec JY (2009) Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness. Biochem Biophys Res Commun 379(2):304–308PubMedCrossRef
39.
Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, Ohmi Y, Yamauchi Y, Furukawa K, Furukawa K (2010) Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 285(35):27213–27223PubMedCrossRefPubMedCentral
40.
Sadej R, Spychala J, Skladanowski AC (2006) Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 16(3):213–222PubMedCrossRef
41.
Wang F, Cao Y, Liu HY, Xu SF, Han R (2003) Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells. J Asian Nat Prod Res 5(2):121–129PubMedCrossRef
42.
Locatelli C, Leal PC, Yunes RA, Nunes RJ, Creczynski-Pasa TB (2009) Gallic acid ester derivatives induce apoptosis and cell adhesion inhibition in melanoma cells: the relationship between free radical generation, glutathione depletion and cell death. Chem Biol Interact 181(2):175–184PubMedCrossRef
43.
Sallam AA, Ramasahayam S, Meyer SA, El Sayed KA (2010) Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration. Bioorgan Med Chem 18(21):7446–7457CrossRef
44.
Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist 18(1):25–26PubMedCrossRefPubMedCentral
45.
Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA (2005) A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280(20):19516–19526PubMedCrossRef
46.
Conner SR, Scott G, Aplin AE (2003) Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem 278(36):34548–34554PubMedCrossRef
47.
Romanchikova N, Trapencieris P, Zemitis J, Turks M (2013) A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation. J Enzyme Inhib Med Chem. doi:10.​3109/​14756366.​2013.​855207 PubMed
48.
Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M, Fishman P (2005) CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 7(1):85–90PubMedCrossRefPubMedCentral
49.
Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA (2007) Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 31(2):36–100PubMedCrossRef
50.
Kim GD, Oh J, Jeong LS, Lee SK (2013) Thio-Cl-IB-MECA, a novel A(3) adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells. Biochem Biophys Res Commun 437(1):79–86PubMedCrossRef
Metadata
Title
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma
Authors
Ana S. Soares
Vera M. Costa
Carmen Diniz
Paula Fresco
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2557-y

Other articles of this Issue 4/2014

Cancer Chemotherapy and Pharmacology 4/2014 Go to the issue

Original Article

Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy

Original Article

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

Original Article

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

Original Article

Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane

Original Article

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

Review Article

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits